Gregory P. Botta, MD, PhD

Articles

Dr. Botta on Unmet Needs in the Salvage Setting of GI Cancers

June 28th 2022

Gregory Botta, MD, PhD, discusses unmet needs in the salvage setting of gastrointestinal cancers.

Dr. Botta on the Rationale of Investigating CT041 in Gastric and Pancreatic Cancers

June 19th 2022

Gregory Botta, MD, PhD, discusses the rationale for investigating CT041 in patients with advanced gastric and pancreatic cancers in a phase 1b trial.

Dr. Botta on the Evaluation of CT041 in Gastric and Pancreatic Cancer

June 7th 2022

Gregory Botta, MD, PhD, discusses the evaluation of CT041 in patients with advanced gastric and pancreatic cancers in a phase 1b trial.

Assessing the Full Potential of ctDNA in Colorectal Cancer

March 22nd 2022

Gregory P. Botta, MD, PhD, highlights key trials of interest exploring ctDNA analyses to better inform treatment decisions for patients with rectal cancers.

CIRCULATE-Japan: Using ctDNA to Guide Adjuvant Therapy in Colorectal Cancer

March 15th 2022

What to know about the design and results of the CIRCULATE-Japan study in colorectal cancer, in terms of using ctDNA analyses to help inform treatment decisions in the postoperative setting.

Future Role of ctDNA in Pancreatic Cancer

March 8th 2022

Current trials investigating the potential of ctDNA analyses in pancreatic cancer.

Personalized/Tumor-Informed ctDNA and Patient Survival in Pancreatic Cancer

March 1st 2022

Dr Gregory P. Botta reacts to results of a study that recently explored the association of tumor-informed and personalized ctDNA with patient survival outcomes in pancreatic cancer, as presented at ASCO GI 2022.

ctDNA Testing in Pancreatic Cancer

February 22nd 2022

The potential clinical applications of ctDNA analyses in pancreatic cancer.

MRD Testing in Solid Tumors

February 15th 2022

The present role of minimal residual disease in solid tumor cancers, and current evaluations further exploring its potential in pancreatic and colorectal cancer.